Cadila gets FDA nod for arthritis drug
Disease Modifying Anti-Rheumatic Drug is a medication for patients with Rheumatoid Arthritis that helps reduce pain and inflammation, prevents joint damage.
By PTI |
NEW DELHI: Pharmaceutical Company Zydus Cadila Healthcare on Tuesday said it received US Food and Drug Administrator's (FDA) approval for a drug used in the treatment of rheumatoid arthritis.
The company has received an approval from FDA for the new Disease Modifying Anti-Rheumatic Drug (DMARD) Hydroxychloroquine Sulfate tablets of 200 mg strength, Cadila said in a report to the Bombay Stock Exchange.
DMARD is a medication for patients with Rheumatoid Arthritis that helps decrease pain and inflammation, prevents joint damage and preserves the structure of the joints. Drugs of this category provide relief over a period of time ranging from a few weeks to a few months.
The company would market the drug through its US-based subsidiary Zydus Pharmaceuticals (USA) Inc, Cadila Healthcare said.
Shares of the company were last trading at Rs 299.05, down 1.40 per cent on BSE.
The company has received an approval from FDA for the new Disease Modifying Anti-Rheumatic Drug (DMARD) Hydroxychloroquine Sulfate tablets of 200 mg strength, Cadila said in a report to the Bombay Stock Exchange.
DMARD is a medication for patients with Rheumatoid Arthritis that helps decrease pain and inflammation, prevents joint damage and preserves the structure of the joints. Drugs of this category provide relief over a period of time ranging from a few weeks to a few months.
The company would market the drug through its US-based subsidiary Zydus Pharmaceuticals (USA) Inc, Cadila Healthcare said.
Shares of the company were last trading at Rs 299.05, down 1.40 per cent on BSE.
Start a SIP with as low as ₹500 with ET Money App!
Download
The Economic Times News App for Quarterly Results, Latest News in ITR, Business, Share Market, Live Sensex News & More.
The Economic Times News App for Quarterly Results, Latest News in ITR, Business, Share Market, Live Sensex News & More.
ADVERTISEMENT
